Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a class of T cell engagers that uses the body's immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers, focused on the treatment of solid tumors and hematologic malignancies. The company has four Tri-specific T cell Activating Construct product candidates: HPN424, which is for the treatment of metastatic castration-resistant prostate cancer; HPN536, which is for the treatment of ovarian cancer and other mesothelin-expressing solid tumors; HPN217, which is for the treatment of multiple myeloma; and HPN328, which is for the treatment of small cell lung cancer.
  • TickerHARP
  • ISINUS41358P1066
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
HARP Harpoon Therape... (Health Care)

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriT...

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021 SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting be...

Robert Driscoll
  • Robert Driscoll
 PRESS RELEASE
HARP Harpoon Therape... (Health Care)

Harpoon Therapeutics Announces Poster Presentations and Publication of...

Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon’s website following the presentation...

Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
 PRESS RELEASE
HARP Harpoon Therape... (Health Care)

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriT...

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021 SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting be...

Robert Driscoll
  • Robert Driscoll
 PRESS RELEASE
HARP Harpoon Therape... (Health Care)

Harpoon Therapeutics Announces Poster Presentations and Publication of...

Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon’s website following the presentation...

Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
 PRESS RELEASE
HARP Harpoon Therape... (Health Care)

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriT...

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021 SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting be...

Robert Driscoll
  • Robert Driscoll
 PRESS RELEASE
HARP Harpoon Therape... (Health Care)

Harpoon Therapeutics Announces Poster Presentations and Publication of...

Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon’s website following the presentation...

Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack

ResearchPool Subscriptions

Get the most out of your insights

Get in touch